Breakthrough Mesothelioma Drug, ADI-PEG20, Quadruples Survival Rates in International Trial

Scientists have achieved a major breakthrough in mesothelioma treatment with the development of ADI-PEG20, a groundbreaking drug that quadrupled three-year survival rates in an international trial spanning five countries.

Led by Queen Mary University of London, the ATOMIC-meso trial involved 249 patients with pleural mesothelioma, demonstrating a significant increase in median overall survival and progression-free survival when ADI-PEG20 was combined with chemotherapy.

This marks the first successful combination with chemotherapy in two decades. The drug operates by depleting arginine levels, hindering the growth of mesothelioma cells lacking the protein ASS1.

It offers another much-needed treatment option and, above all, hope to those living with mesothelioma." The hope now is for this treatment to become a standard option for all mesothelioma patients in the future.

Liz Darlison, CEO of Mesothelioma UK

The study was funded by Cancer Research UK and the biotechnology company Polaris Group, showcasing the collaborative efforts to delve deep into the biology of mesothelioma.

Dr. Tayyaba Jiwani of Cancer Research UK highlighted the power of discovery research in identifying vulnerabilities in mesothelioma that could be effectively targeted with ADI-PEG20.

You can read the full story here.

5 1 vote
Article Rating
Notify of
Inline Feedbacks
View all comments